Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Vyankatesh K Shivane"'
Autor:
Sae Jeong Yang, Kyung Wan Min, Sandeep Kumar Gupta, Joong Yeol Park, Vyankatesh K. Shivane, Pankaj Kumar Agarwal, Doo Man Kim, Yong Esong Kim, Sei Hyun Baik
Publikováno v:
Diabetes & Metabolism Journal, Vol 45, Iss 4, Pp 606-612 (2021)
The purpose of this extension study was to assess the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus (T2DM). Patients with T2DM who had completed the initial 24-week study comparing gemigliptin monotherap
Externí odkaz:
https://doaj.org/article/ee2aada195b1403497faf4f8f7fcc9b0
Autor:
Doo Man Kim, Vyankatesh K Shivane, Sandeep Kumar Gupta, Sei Hyun Baik, Pankaj Kumar Agarwal, Yong Esong Kim, Joong Yeol Park, Kyung Wan Min, Sae Jeong Yang
Publikováno v:
Diabetes & Metabolism Journal
Diabetes & Metabolism Journal, Vol 45, Iss 4, Pp 606-612 (2021)
Diabetes & Metabolism Journal, Vol 45, Iss 4, Pp 606-612 (2021)
The purpose of this extension study was to assess the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus (T2DM). Patients with T2DM who had completed the initial 24-week study comparing gemigliptin monotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a2f233c5dc896f34c15aaefeebf92d2
https://doi.org/10.4093/dmj.2020.0047
https://doi.org/10.4093/dmj.2020.0047
Autor:
Shareque T. Shaikh, DD, Swati S. Jadhav, MD, Vyankatesh K. Shivane, DD, Anurag R. Lila, DM, Tushar R. Bandgar, DM, Nalini S. Shah, DM
Publikováno v:
AACE Clinical Case Reports, Vol 2, Iss 2, Pp e117-e121 (2016)
ABSTRACT: Objective: To describe an atypical childhood onset presentation of sulfonylurea-responsive neonatal diabetes mellitus (NDM) resulting from the unusually late expression of a homozygous, novel ABCC8 gene mutation. Onset was at 9 years of age
Externí odkaz:
https://doaj.org/article/50e73a9e291842a9b30abe5d9f604170
Autor:
Eun-Jung Rhee, Won Young Lee, Hak Chul Jang, Vyankatesh K Shivane, Kyung Wan Min, Il Seong Nam-Goong, Chan-Hee Jung, Aravind R Sosale, Choon Hee Chung
Publikováno v:
Diabetes, obesitymetabolism. 20(6)
We investigated the long-term efficacy and safety of gemigliptin and the efficacy and safety of gemigliptin treatment after once-daily treatment with sitagliptin 100 mg, in patients with type 2 diabetes. This was a 28-week extension of a 24-week, ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a943c316755a55b786081bc50c2f173
https://pubmed.ncbi.nlm.nih.gov/29436761
https://pubmed.ncbi.nlm.nih.gov/29436761
Autor:
Viswanathan Mohan, S. H. Baik, U. Mahesh, P. K. Kim, P. Gandhi, J. A. Kim, Kyung Wan Min, M. Dharmalingam, S. K. Gupta, P. K. Agarwal, A. Sosale, S. U. Pitale, Joong Yeol Park, Vyankatesh K Shivane, Sae Jeong Yang, Y. S. Kim, Doo Man Kim
Publikováno v:
Diabetes, Obesity and Metabolism. 15:410-416
Aim This study was designed to assess the efficacy and safety of the dipeptidyl peptidase IV inhibitor gemigliptin (LC15-0444) 50 mg versus placebo in patients with type 2 diabetes. Methods We conducted a 24-week, randomized, double-blind, placebo-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94a383564269557ebb1b31f286463021
https://doi.org/10.1111/dom.12042
https://doi.org/10.1111/dom.12042